Atrium Therapeutics launched Friday morning as Novartis closed the $12 billion deal to buy Avidity Biosciences and its RNA muscle therapies.
The spinout will take on Avidity’s early-stage programs for genetic cardiomyopathies — heart muscle diseases ...
↧